저분자 API : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the small molecule API market size is expected to increase from USD 171.97 billion in 2025 to USD 182.88 billion in 2026 and reach USD 250.26 billion by 2031, growing at a CAGR of 6.45% over 2026-2031.

This report is Segmented by Type (Synthetic, Biological), by Manufacturer (In-House, Outsourced), by Therapeutic Area (Oncology, Cardiovascular Diseases, and More), and by Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Small Molecule API Market Trends and Insights

Rising Chronic Disease Burden and Long-Term Therapy Volumes

The Small molecule API market is benefiting from a steady rise in chronic disease treatment needs across oncology, cardiometabolic care, and long-duration maintenance therapies. Longer treatment duration matters as much as rising diagnosis volume, because products used over many months or years create recurring API demand rather than short refill cycles. This supports the Small molecule API market because approved therapies in targeted oncology and chronic cardiometabolic care tend to hold predictable replenishment patterns once adoption broadens. It also favors manufacturers with established regulatory files and dependable scale, since buyers usually prefer proven supply continuity when treatment duration is long.

Patent Expiries and Generic Substitution Cycles

The Small molecule API market is entering a favorable period for generic supply preparation as a larger set of established small molecule drugs moves closer to loss of exclusivity. That process tends to increase API qualification activity, filing work, and commercial supply planning well before the first generic launch. India is well-positioned in this cycle, with API exports reaching INR 41,500 crore, or USD 4.88 billion, in FY2025 and exceeding the country's pharmaceutical imports for the first time. The effect on the Small molecule API market is broader than a simple volume increase, because generic entry also brings new sourcing bids, second-source qualification work, and tighter lead-time expectations from formulators. Suppliers that already have compliant processes, raw material access, and filing readiness are therefore in a stronger position to capture this wave.

Nitrosamine, Impurity, and Traceability Compliance Burden

The Small molecule API market faces a clear restraint from tighter impurity control, especially where nitrosamine risk assessment and traceability requirements are expanding. The FDA updated its nitrosamine impurity guidance in June 2025 and required manufacturers to provide confirmatory testing progress updates by August 1, 2025. The EMA also maintains a detailed framework for managing nitrosamine impurities, which means companies serving multiple regulated markets must sustain broad documentation, analytical, and process review efforts. In the Small molecule API market, these requirements increase cost even before a product change reaches commercial scale, because suppliers must review formation pathways, method suitability, and downstream specifications together. Older batch assets are more exposed where contamination pathways are harder to control, which gradually shifts competitiveness toward plants with newer systems and better process visibility.

Other drivers and restraints analyzed in the detailed report include:

1. Outsourcing Shift Toward CDMOs for Cost and Capacity Flexibility
2. Expansion of High Potency and Complex Small Molecule Pipelines
3. Feedstock and Solvent Supply Volatility

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Synthetic APIs accounted for 86.18% of the Small molecule API market in 2025, which shows how deeply established chemical synthesis remains across cardiovascular, anti-infective, CNS, and metabolic therapies. This category benefits from mature regulatory pathways, broad plant availability, and cost structures that fit large generic and branded volumes. Biological APIs, which include semi-synthetic fermentation-based routes and bio-transformation processes, are forecast to expand at 7.83% CAGR from 2026 to 2031. That makes them the faster-moving complement inside the Small molecule API market, especially where oncology-linked derivatives and more specialized process routes are becoming more relevant.

The split is not purely a volume issue, because many newer programs use a mix of synthetic and biologically assisted steps rather than one route alone. That favors companies that can combine process chemistry, biocatalysis, and analytical control in one development chain. The FDA's increasing attention to advanced manufacturing methods and the continued regulatory push around process consistency are also raising the execution standard for both categories in the Small molecule API market. Over time, synthetic dominance is likely to stay intact on value share, but the faster expansion of biological APIs should keep the segment mix gradually moving toward more specialized manufacturing content.

Complete Report Scope:

• By Type
  • Synthetic
  • Biological
• By Manufacturer
  • In-House
  • Outsourced
• By Therapeutic Area
  • Oncology
  • Cardiovascular Diseases
  • Central Nervous System and Neurology
  • Infectious Diseases
  • Metabolic Disorders
  • Respiratory Disorders
  • Gastroenterology
  • Ophthalmology
  • Dermatology
  • Urology
  • Others (Endocrinology, Nephrology, etc.)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

Asia-Pacific held 47.18% of the Small molecule API market share in 2025 and is projected to grow at 8.43% CAGR from 2026 to 2031. China remains central to regional manufacturing depth, while India is strengthening its export and domestic substitution role within the Small molecule API market. India's bulk drug PLI scheme had commissioned 38 projects across 28 notified products by December 2025, with cumulative sales of INR 2,720 crore, or USD 319 million. The same government update stated that 191 APIs, key starting materials, and drug intermediates were being produced domestically for the first time under the scheme. India also recorded API exports of INR 415.0 billion (~USD 4.88 billion) in FY2025, which marked the first year exports surpassed pharmaceutical imports.

North America remains a critical sponsor and sourcing region for the small-molecule API market because development decisions, regulatory oversight, and commercial qualification activity remain deeply concentrated there. Proposed U.S. tariff measures and broader supply security concerns are accelerating interest in domestic and friend-shored API capacity. Cambrex responded with a USD 120 million plan for a new large-scale API plant in Charles City, Iowa, with groundbreaking scheduled for late 2026.

Europe remains the second major regional base in the Small molecule API market, supported by a mature ecosystem across Germany, the United Kingdom, France, Italy, and Spain. The European Union is pushing supply resilience through policy support, and EUROAPI secured up to EUR 140 million, or USD 154 million, in public aid under the France 2030 plan for three innovation programs tied to pharmaceutical sovereignty. At the same time, Medicines for Europe documented long-term price stagnation and decline in generic medicines across many member states, which limits the cash available for resilience investment.

1. Abbvie
2. Albemarle Corporation
3. Asymchem Laboratories Co., Ltd.
4. Aurobindo Pharma Ltd.
5. BASF
6. Boehringer Ingelheim
7. Bristol-Myers Squibb
8. Cambrex
9. Cipla
10. Divi's Laboratories Limited
11. Dr. Reddy's Laboratories
12. EUROAPI S.A.
13. Evonik Industries
14. Hikma Pharmaceuticals
15. Lonza Group
16. Merck
17. Pfizer
18. Siegfried Holding AG
19. Sun Pharmaceuticals Industries
20. Teva Pharmaceutical Industries

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Chronic Disease Burden and Long-Term Therapy Volumes
  • 4.2.2 Patent Expiries and Generic Substitution Cycles
  • 4.2.3 Outsourcing Shift Toward CDMOs for Cost and Capacity Flexibility
  • 4.2.4 Expansion of High Potency and Complex Small Molecule Pipelines
  • 4.2.5 Friend-Shoring of Critical API Capacity and Dual-Sourcing Programs
  • 4.2.6 Continuous Manufacturing and Inline Analytics Improving Batch Economics
• 4.3 Market Restraints
  • 4.3.1 Nitrosamine, Impurity, and Traceability Compliance Burden
  • 4.3.2 High Containment, Solvent Recovery, and Waste Treatment Capex
  • 4.3.3 Feedstock and Solvent Supply Volatility
  • 4.3.4 Tender-Led Generic Pricing Pressure in Large Volume APIs
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

• 5.1 By Type
  • 5.1.1 Synthetic
  • 5.1.2 Biological
• 5.2 By Manufacturer
  • 5.2.1 In-House
  • 5.2.2 Outsourced
• 5.3 By Therapeutic Area
  • 5.3.1 Oncology
  • 5.3.2 Cardiovascular Diseases
  • 5.3.3 Central Nervous System and Neurology
  • 5.3.4 Infectious Diseases
  • 5.3.5 Metabolic Disorders
  • 5.3.6 Respiratory Disorders
  • 5.3.7 Gastroenterology
  • 5.3.8 Ophthalmology
  • 5.3.9 Dermatology
  • 5.3.10 Urology
  • 5.3.11 Others (Endocrinology, Nephrology, etc.)
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 AbbVie Inc.
  • 6.3.2 Albemarle Corporation
  • 6.3.3 Asymchem Laboratories Co., Ltd.
  • 6.3.4 Aurobindo Pharma Ltd.
  • 6.3.5 BASF SE
  • 6.3.6 Boehringer Ingelheim International GmbH
  • 6.3.7 Bristol-Myers Squibb Company
  • 6.3.8 Cambrex Corporation
  • 6.3.9 Cipla Ltd.
  • 6.3.10 Divi's Laboratories Limited
  • 6.3.11 Dr. Reddy's Laboratories Ltd.
  • 6.3.12 EUROAPI S.A.
  • 6.3.13 Evonik Industries AG
  • 6.3.14 Hikma Pharmaceuticals PLC
  • 6.3.15 Lonza Group AG
  • 6.3.16 Merck KGaA
  • 6.3.17 Pfizer Inc.
  • 6.3.18 Siegfried Holding AG
  • 6.3.19 Sun Pharmaceutical Industries Ltd.
  • 6.3.20 Teva Pharmaceutical Industries Ltd.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment